The NCCN clinical practice guideline in genetic high-risk assessment for breast, ovarian, and pancreatic cancer does not recommend pancreatic cancer screening for BRCA1 and BRCA2 mutation carriers in the absence of a close family history of exocrine pancreatic cancer [37]. This evidence concerns the gene BRCA2 and familial pancreatic carcinoma.